Refine by
Therapeutics Transforming Drug Articles & Analysis: This-Year
4 news found
Watertown, MA - June 29, 2025 - Biopharma PEG, a leading innovator in high-quality polyethylene glycol (PEG) derivatives, today announced it has successfully obtained Drug Master File (DMF) approval from the U.S. Food and Drug Administration (FDA) for its self-developed HZ-PEG-HZ (1K) product. The assigned DMF number is 041864. This significant achievement underscores Biopharma PEG's robust ...
BOC Sciences adds to its participation agenda the prestigious Drug Discovery Chemistry 2025 Conference (April 14-17, 2025), which will be a hybrid event taking place in San Diego, CA, and will offer virtual access for worldwide attendees Drug Discovery Chemistry is a heavyweight industry event. It draws thousands of scientists, biotech innovators, and pharmaceutical executives ...
Ace Therapeutics, a preclinical contract research provider dedicated to offering comprehensive one-stop services, released the expansion of its research capabilities in the area of depression through the introduction of comprehensive depression-related behavior tests in its preclinical investigation processes. This integral development aims to enhance the understanding of depressive disorders and ...
Changsha, China – Hunan Huateng Pharmaceutical Co., Ltd. (Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. This achievement highlights Huateng Pharma’s ...